Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schleifer, Yancopoulos And The $36 Billion Friendship

In 1988 Len Schleifer took a talented scientist, George Yancopoulos, out to dinner to persuade the immunologist to join his newly formed company. Thirty years, six drug approvals and many arguments later, pharma’s most famous friendship is now looking to change the way allergies are treated.

Commercial Leadership Outlook 2019

Lessons From A Life Sciences Lifetime: An Interview With Sir John Bell

Professor Sir John Bell talks to In Vivo about how the life sciences sector has evolved during his career, lessons he has learned along the way, and the biggest challenges and changes ahead for the industry in 2019.

Leadership Brexit Outlook 2019

Strategy At Novartis: Culture Change As The 'How' Behind The 'What'

If strategic planning is a necessary hedge against the drawn-out, asset-draining product cycles of today’s big pharma enterprise, then what is the secret of doing it well? Scrip looks for answers in a conversation with Novartis strategy lead Stephen Moran.

Leadership Strategy Companies

Interview: Silence Therapeutics’ Chair On Why Keeping Quiet Has Done The Biotech No Favors

Silence Therapeutics’ executive chair, Annalisa Jenkins, talks to Scrip about why there’s more to the company than a court case.

Commercial Leadership Legal Issues

R&D Heads At GSK & AZ Say Key To Success Lies In Smart Risk Taking

AZ's Mene Pangalos and GSK's Hal Barron are at different stages of overseeing culture changes in their respective R&D workforces - but both agreed at a recent conference that such transformations are key for the future viability of their drug companies.

Business Strategies Commercial Companies

UsernamePublicRestriction

Register